The FGL-1/LAG-3 interaction blockade stimulates tumor immunity [67]. The reduced expression of FGL-1 increases the efficiency of CD8+ T-cell activation during LAG-3 blockade [69]. The gene discussed is CD8A; the disease is neoplasm.